FDA's Vinay Prasad resigned after backlash over pausing Sarepta's Elevidys gene therapy, following deaths linked to treatment. Critics accused him of restricting access to a life-saving drug. Sarepta later resumed shipments for ambulatory patients only. Retail sentiment turned 'extremely bullish' on Stocktwits despite the stock's 87% YTD drop.